journal article·2022-11Open access

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Elisabeth Fuchs, Imke Rudnik-Jansen, Anders Dinesen, Denis Selnihhin, Ole Aalund Mandrup, Kader Thiam, Jørgen Kjems, Finn Skou Pedersen, Kenneth A. Howard

Acta Biomaterialia· Volume 153

Abstract

The emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants and breakthrough infections despite available coronavirus disease 2019 (COVID-19) vaccines calls for antiviral therapeutics. The application of soluble angiotensin converting enzyme 2 (ACE2) as a SARS-CoV-2 decoy that reduces cell bound ACE2-mediated virus entry is limited by a short plasma half-life. This work presents a recombinant human albumin ACE2 genetic fusion (rHA-ACE2) to increase the plasma half-life by an FcRn-driven cellular recycling mechanism, investigated using a wild type (WT) albumin sequence and sequence engineered with null FcRn binding (NB). Binding of rHA-ACE2 fusions to SARS-CoV-2 spike protein subdomain 1 (S1) was demonstrated (WT-ACE2 KD = 32.8 nM and NB-ACE2 KD = 31.7 nM) using Bio-Layer Interferometry and dose-dependent in vitro inhibition of host cell infection of pseudotyped viruses displaying surface SARS-CoV-2 spike (S) protein. FcRn-mediated in vitro recycling was translated to a five times greater plasma half-life of WT-ACE2 (t½ β = 13.5 h) than soluble ACE2 (t½ β = 2.8 h) in humanised FcRn/albumin double transgenic mice. The rHA-ACE2-based SARS-CoV-2 decoy system exhibiting FcRn-driven circulatory half-life extension introduced in this work offers the potential to expand and improve the anti-COVID-19 anti-viral drug armoury. The COVID-19 pandemic has highlighted the need for rapid development of efficient antiviral therapeutics to combat SARS-CoV-2 and new mutants to lower morbidity and mortality in severe cases, and for people that are unable to receive a vaccine. Here we report a therapeutic albumin ACE2 fusion protein (rHA-ACE2), that can bind SARS-CoV-2 S protein decorated virus-like particles to inhibit viral infection, and exhibits extended in vivo half-life compared to ACE2 alone. Employing ACE2 as a binding decoy for the virus is expected to efficiently inhibit all SARS-CoV-2 mutants as they all rely on binding with endogenous ACE2 for viral cell entry and, therefore, rHA-ACE2 constitutes a versatile addition to the therapeutic arsenal for combatting COVID-19.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · SARS-CoV-2 and COVID-19 Research · Advanced Biosensing Techniques and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. A pneumonia outbreak associated with a new coronavirus of probable bat origin10.1038/s41586-020-2012-7 ↗
2. WHO. WHO coronavirus (COVID-19) dashboard. 2022 [cited 2022 23/02]; Available from: https://covid19.who.int/.
3. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults10.1056/NEJMoa2028436 ↗
4. The Johnson & Johnson vaccine for COVID-1910.1001/jama.2021.2927 ↗
5. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial10.1016/S0140-6736(20)32466-1 ↗
6. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial10.1001/jama.2021.8565 ↗
7. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant10.1056/NEJMoa2103055 ↗
8. Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments10.1016/j.vaccine.2021.10.068 ↗
9. Inactivated vaccines may not provide adequate protection in immunosuppressed patients with rheumatic diseases10.1136/annrheumdis-2021-221496 ↗
10. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines10.1016/j.ymthe.2021.01.030 ↗
11. COVID-19 vaccines and variants of concern: a review10.1002/rmv.2313 ↗
12. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel10.2807/1560-7917.ES.2021.26.26.2100557 ↗
13. Williams, S.V., A. Vusirikala, S.N. Ladhani, E. Fernandez Ruiz De Olano, N. Iyanger, F. Aiano, K. Stoker, G. Gopal Rao, L. John, B. Patel, N. Andrews, G. Dabrera, M. Ramsay, K.E. Brown, J. Lopez Bernal, and V. Saliba, An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. 2021. 26(27): p. 2100626.10.2807/1560-7917.ES.2021.26.27.2100626 ↗
14. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic10.1016/j.cell.2021.12.032 ↗
15. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor10.1016/j.cell.2020.02.052 ↗
16. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects10.1007/s40262-013-0072-7 ↗
17. Llewellyn-Davies, P. APEIRON's APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial. 12/03/, 2021, [press release]. Available from: https://www.apeiron-biologics.com/wp-content/uploads/20210312_PR_APN01-topline-data_ENG.pdf.
18. Human recombinant soluble ACE2 in severe COVID-1910.1016/S2213-2600(20)30418-5 ↗
19. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury10.1007/s11427-020-1643-8 ↗
20. The emerging role of ACE2 in physiology and disease10.1002/path.2162 ↗
21. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig10.1038/s41467-020-16048-4 ↗
22. An ACE2 microbody containing a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-210.1016/j.celrep.2020.108528 ↗
23. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy10.1080/19420862.2020.1804241 ↗
24. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells10.1172/JCI119110 ↗
25. Current concepts in the diagnosis and management of cytokine release syndrome10.1182/blood-2014-05-552729 ↗
26. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies10.1038/s41564-020-00789-5 ↗
27. Peters · 1996 · 432
28. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin10.1074/jbc.M117.794248 ↗
29. Albumin-based drug delivery: harnessing nature to cure disease10.1186/s40591-016-0048-8 ↗
30. Albumin-based drug designs for pharmacokinetic modulation10.1080/17425255.2020.1801633 ↗
31. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor10.1038/ncomms1607 ↗
32. An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics10.1126/scitranslmed.abb0580 ↗
33. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry10.1073/pnas.2112942118 ↗
34. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs10.1016/j.jconrel.2015.12.019 ↗
35. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement10.1016/j.jconrel.2018.07.023 ↗
36. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection10.15252/emmm.202012828 ↗
37. An ACE2 triple decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants10.1038/s41598-021-91809-9 ↗
38. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo10.1038/s41421-021-00302-0 ↗
39. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures10.1038/s41587-020-0577-1 ↗
40. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity10.1038/s42003-021-01790-2 ↗
41. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies10.1007/s00228-020-02963-4 ↗
42. In vitro and in vivo models for studying SARS-CoV-2, the etiological agent responsible for COVID-19 pandemic10.3390/v13030379 ↗
43. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system10.1016/j.cell.2021.02.053 ↗
44. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-910.1161/01.RES.87.5.e1 ↗
45. An intact C-terminal end of albumin is required for its long half-life in humans10.1038/s42003-020-0903-7 ↗
46. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering10.1016/j.pep.2008.04.013 ↗